Biomodels was founded in 1997 when Dr. Edward Fey, then employed by Brigham and Women’s Hospital’s Office of Technology Transfer, Dr. Stephen T. Sonis, and Harry Barnett recognized that in many instances pharmaceutical companies made the transition from the laboratory to the clinic based largely on faith, rather than on results obtained in sound, predictive models of the intended clinical application.
Dr. Fey, himself a founder of a successful cancer diagnostic company, realized that many of the models used by Brigham investigators could be adapted for drug development and modified to focus on clinical endpoints. With the Brigham’s support, and using models developed by Dr. Stephen Sonis for the study of cancer therapy-induced mucositis, the company was started.
In the past 18 years, Biomodels has expanded in personnel, space, and scope of studies. In 2005, Biomodels moved to its current location in Watertown, MA. The new location allowed for rapid expansion. In 2012 Daniel Lichtman joined Biomodels as the Managing Partner and shortly thereafter, then Director of Research Dr. Gregory D. Lyng also became a partner. That same year the company added a second floor to the facility, effectively doubling in size then further expanding in 2015 with an additional 8,000 square feet. The now 20,000 square foot facility supports multiple vivariums, procedure rooms, and professional space. During the expansion, Biomodels was dedicated to developing a state of the art facility which supports a wide range of models in oncology, cancer supportive care, mucosal and inflammatory diseases, cardiovascular and metabolic diseases, behavioral testing, in vitro services and genomics. The changes continue even today, as the commitment to innovation means that Biomodels is constantly updating instrumentation, techniques, and space to ensure client studies are conducted with the best tools available.